Literature DB >> 8212149

An analysis of liver transplant experience from 37 transplant centers as reported to Medicare.

V E Kilpe1, H Krakauer, R E Wren.   

Abstract

Analysis of 5180 liver transplant cases from 37 liver transplant centers in the United States (1982-1991) shows an overall one-year survival rate of 79.4 +/- 0.6% and a five-year survival rate of 69.2 +/- 0.9%. There was marked improvement in the one-year survival rate after liver transplantation from 36.0 +/- 9.6% in 1982 to 85.0 +/- 1.8% in 1991. One-year survival rates after liver transplantation for postnecrotic cirrhosis, primary biliary cirrhosis, alcoholic cirrhosis, primary sclerosing cholangitis, alpha-1-antitrypsin deficiency, and Wilson's disease ranged from 78.4 +/- 1.0% to 84.2 +/- 1.5% and five-year survival rates from 68.6 +/- 3.8% to 79.2 +/- 5.3%. Survival rates after liver transplantation for hemochromatosis were poor--a one-year survival rate of 53.8 +/- 6.8% and a five year survival rate of 43.1 +/- 11%. One- and five-year survival rates for the 0-13 years age group were 74.6 +/- 2.8% and 66.7 +/- 3.4%; for the 14-37 years age group, 83.3 +/- 1.2% and 73.8 +/- 1.8%; for the 38-54 years age group, 79.6 +/- 0.8% and 69.7 +/- 1.3%; for the 55-63 years age group, 76.0 +/- 1.4% and 63.0 +/- 3.1%; and for the 64-77 years age group, 76.5 +/- 3.0% and 65.4 +/- 4.6%.

Entities:  

Mesh:

Year:  1993        PMID: 8212149     DOI: 10.1097/00007890-199309000-00012

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  15 in total

1.  Estimating future hepatitis C morbidity, mortality, and costs in the United States.

Authors:  J B Wong; G M McQuillan; J G McHutchison; T Poynard
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

2.  The diagnosis and management of hereditary haemochromatosis.

Authors:  Paul Clark; Laurence J Britton; Lawrie W Powell
Journal:  Clin Biochem Rev       Date:  2010-02

3.  Causes of late mortality in pediatric liver transplant recipients.

Authors:  D L Sudan; B W Shaw; A N Langnas
Journal:  Ann Surg       Date:  1998-02       Impact factor: 12.969

4.  Disease gravity and urgency of need as guidelines for liver allocation.

Authors:  B Eghtesad; O Bronsther; W Irish; A Casavilla; K Abu-Elmagd; D Van Thiel; A Tzakis; J J Fung; T E Starzl
Journal:  Hepatology       Date:  1994-07       Impact factor: 17.425

5.  Spur cell anaemia and hepatic iron stores in patients with alcoholic liver disease undergoing orthotopic liver transplantation.

Authors:  A Pascoe; P Kerlin; C Steadman; A Clouston; D Jones; L Powell; E Jazwinska; S Lynch; R Strong
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

6.  Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

Authors:  U Siebert; G Sroczynski; S Rossol; J Wasem; U Ravens-Sieberer; B M Kurth; M P Manns; J G McHutchison; J B Wong
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

7.  Prognostic factors and survival in patients with hereditary hemochromatosis and cirrhosis.

Authors:  Melanie D Beaton; Paul C Adams
Journal:  Can J Gastroenterol       Date:  2006-04       Impact factor: 3.522

8.  One thousand liver transplants. The lessons learned.

Authors:  R W Busuttil; A Shaked; J M Millis; O Jurim; S D Colquhoun; C R Shackleton; B J Nuesse; M Csete; L I Goldstein; S V McDiarmid
Journal:  Ann Surg       Date:  1994-05       Impact factor: 12.969

9.  Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.

Authors:  Sean D Sullivan; Antonio Craxi; Alfredo Alberti; Giovanni Giuliani; Claudio De Carli; Neil Wintfeld; Kavita K Patel; Jesse Green
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

10.  Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.

Authors:  Uwe Siebert; Gaby Sroczynski; Pamela Aidelsburger; Siegbert Rossol; Jürgen Wasem; Michael P Manns; John G McHutchison; John B Wong
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.